Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk

Pharmacogenetics

Volumn 9, Issue 1, 1999, Pages 103-111

  Henning, Stefan ^a,b   Cascorbi, Ingolf ^a   Münchow, Beate ^a   Jahnke, Volker ^b   Roots, Ivar ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acetylator genotype; Larynx carcinoma; Molecular epidemiology; Smoking

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ACETYLATION; ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LARYNX CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032939821     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199902000-00014     Document Type: Article

References (36)

1. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996; 276:1494-1501.
2. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Roots I. Arylamine N-acelyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics 1997; 7:327-331.
3. Bell DA, Badawi AF, Lang NP, Hettl KF, Kadlubar FF, Hlrvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association of NAT1‡10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995; 55:5226-5229.
4. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferase M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56:3915-3925.
5. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2:842-845.
6. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57:581-592.
7. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I. Homozygous rapid arylamine N-acelyltransferase (NAT2) genotype as susceptibility factor for lung cancer. Cancer Res 1996a; 56:3961-3966.
8. Cascorbi I, Brockmöller J, Bauer S, Reum T, Roots I. NAT2*12A (803A → G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics 1996b; 6:257-260.
9. Copper MP, Javonavic A, Nauta JJP, Braakhuis BJM, de Vries N, van der Waal I, Snow GB. Role of genetic factors in the etiology of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1997; 121:157-160.
10. Coutelle C, Ward PJ, Fleury B, Quattrocchi P, Chambrin H, Iron A, et al. Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum Genet 1997; 99:319-325.
11. Degawa M, Stern SJ, Martin MV, Guengerich FP, Fu PP, Hett KF, et al. Metabolic activation and carcinogen-DNA adduct detection in human larynx. Cancer Res 1994; 54:4915-4919.
12. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995; 5:259-274.
13. Franceschi S, Gloghini A, Maestro R, Barzan L, Bidoli E, Talamini R, et al. Analysis of the p53 gene in relation to tobacco and alcohol in cancers of the upper aero-digestive tract. Int J Cancer 1995; 60:872-876.
14. Gil JP, Lechner MC. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis 1998; 19:37-41.
15. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ. Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14:1633-1638.
16. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 1994; 3:729-734.
17. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev 1998; 7:19-23.
18. Lang NP, Kadlubar FF. Aromatic and heterocyclic amine metabolism and phenotyping in humans. Prog Clin Biol Res 1991; 372:33-47.
19. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT, N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 1979; 29:71-79.
20. Maier H, de Vries N, Weidauer H. Occupation and cancer of the oral cavity, pharynx, and larynx. HNO 1990; 38:271-278.
21. Maier H, Tisch M. Epidemiology of laryngeal cancer: results of the Heidelberg case-control study. Acta Otolaryngol Suppl (Stockholm) 1997; 527:160-164.
22. Matas N, Thygesen P, Stacey M, Risch A, Sim E. Mapping AAC1, AAC2, and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes in human chromosome 8p22, a region frequently deleted in tumours. Cytogenet Cell Genet 1997; 77:290-295.
23. Matthias C, Bockmühl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, et al. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 1998; 8:90-100.
24. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase (NAT2) gene in the Polish population. Clin Pharm Ther 1996; 59:376-382.
25. Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 1997; 6:225-231.
26. Probst-Hensch NM, Haile RW, Li DS, Sakamoto GT, Louie AD, Lin BK, et al. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis 1996; 17:2125-2129.
27. Raitiola HS, Pukander JS. Etiological factors of laryngeal cancer. Acta Otolaryngol Suppl (Stockholm) 1997; 529:215-217.
28. Risch A, Wallace DMA, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995; 4:231-236.
29. Roberts-Thomson IC, Ryan P, Khoo KK, Hart WJ, McMichael AJ. Butler RN. Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet 1996; 374:1372-1374.
30. Sarkar FH, Sakr WA, Li YW, Jacobs J, Crissman JD. Tumor suppressor p53 gene mutation in squamous cell carcinoma of the larynx. Diagn Mol Pathol 1996; 5:201-205.
31. Szyfler K, Hemminki K, Snyfter W, Smeja Z, Banaszewski J, Yang K. Aromatic DNA adducts in larynx biopsies and leukocytes. Carcinogenesis 1994; 15:2195-2199.
32. Trizna Z, Clayman GL, Spitz MR, Briggs KL, Goepfert H. Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am J Surg 1995; 170:499-501.
33. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci U S A 1991; 88:6333-6337.
34. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5:1-17.
35. Welfare MR, Cooper J, Bassendine MF, Daly AK. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997; 18:1351-1354.
36. Zhang LF, Hemminki K, Szyfter K, Szyfter W, Soderkvist P. p53 mutations in larynx cancer. Carcinogenesis 1994; 15:2949-2951.